NOL3

Across TCGA pan-cancer cohorts, NOL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NOL3 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NOL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where NOL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.421	0.835	<.001	43	view →
PDAC	DFS	Tertile	All	0.720	0.969	<.001	39	view →
LSCC	DFS	Median	III,IV	0.616	1.000	.008	18	view →
CCRCC	OS	Tertile	All	0.745	0.902	.018	12	view →
UCEC	DFS	Median	All	0.951	0.856	.024	8	view →
GBM	OS	Quartile	All	0.741	0.970	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NOL3–LUAD (DFS)

Open the LUAD breakdown →